8-K current report · filed Oct 23, 2026

Zymeworks Inc. (ZYME) 8-K Current Report: October 23, 2026

Item 1.01Item EX-99.1Item 7.01ZYME overview

Short answer

Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Roche receives exclusive worldwide rights to ZW209, a DLL3-targeting trispecific T-cell engager, materially outsourcing development and commercialization.

Zymeworks Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Roche receives exclusive worldwide rights to ZW209, a DLL3-targeting trispecific T-cell engager, materially outsourcing development and commercialization
  • $55 million upfront payment, plus $40 million upon Phase Ib initiation
  • Up to $718 million in research, development, commercial, and sales milestones
  • Tiered high-single-digit to mid-teen royalties on net sales, subject to customary reductions
  • Zymeworks funds Phase Ia activities at Roche’s expense, while Roche assumes later development, manufacturing, and commercialization costs

Item 7.01 · Regulation FD Disclosure

  • Press release announces information regarding Zymeworks’ Collaboration and License Agreement
  • Agreement update may affect strategic partnerships, licensing economics, and future revenue potential

Item EX-99.1 · Exhibit EX-99.1

  • Exclusive global Roche license for ZW209, transferring subsequent development and commercialization responsibility to Roche
  • $55 million upfront plus $40 million upon Phase 1b initiation, improving near-term funding visibility
  • Up to $718 million in additional milestones plus tiered high-single-digit to mid-teen royalties on global net sales
  • Zymeworks retains Phase 1a collaboration, while Roche funds the trial and assumes later global development costs
  • Closing remains subject to HSR waiting-period expiration and customary regulatory conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Zymeworks Inc. 8-K filings

Get the next ZYME 8-K as it lands

Follow ZYME for push alerts, or ask the research agent what this filing means.